RBCC and N3D Continue Strong Promotional Push With MAD Scientist Contest

  RBCC and N3D Continue Strong Promotional Push With MAD Scientist Contest

Business Wire

NOKOMIS, Fla. -- September 18, 2013

As part of their ongoing efforts to publicize the breakthrough capabilities of
the new Bio-Assembler 3D cell culturing system, Rainbow Coral Corp. (OTCBB:
RBCC) and its joint venture partner Nano3D Biosciences (n3D) will reanimate
last year’s highly successful MAD Scientist Contest to help introduce a new
crop of bio-researchers to the device.

The MAD Scientist Contest is an inventive discovery competition challenging
participants to illustrate how 3-D, levitated cultures improve data and
achieve results impossible with other cell-culturing systems. Contestants will
vie for thousands of dollars in prizes and grants with experiments exhibiting
the in-vivo-like characteristics of cell cultures created using n3D's magnetic
levitation and nanoparticle assembly tech.

The top cash prize for 2012 was awarded to Hamsa Jaganathan, Ph.D., of the
Methodist Hospital Research Institute for her amazing model of a breast tumor
microenvironment, created by co-culturing breast cancer cells and fibroblasts.
In addition to inspiring outside-the-box thinking among cellular biologists,
the MAD Scientist Contest will also serve to introduce n3D's Bio-Assembler
system to the young scientists who will lead cellular research into the
future.

Rainbow BioSciences acquired an equity interest in n3D last year, positioning
the company to participate in the potentially impressive upside in store for
n3D. The MAD Scientist Contest promotion is central to n3D and RBCC's ongoing
efforts to build strong awareness and interest in the Bio-Assembler among
researchers across a broad spectrum of scientific and research disciplines.

Rainbow Biosciences is dedicated to the marketing and development of new
medical and research technology innovations designed to help capture a growing
share of a booming biotech industry alongside Bristol Myers Squibb Co. (NYSE:
BMY), Biogen Idec Inc. (NASDAQ: BIIB), Abbott Laboratories (NYSE: ABT) and
Amgen Inc. (NASDAQ: AMGN).

For more information on RBCC’s partnership with n3D and other biotech
initiatives, please visit www.rainbowbiosciences.com/investors.html.

About Rainbow Biosciences

Rainbow Biosciences, LLC, is a wholly owned subsidiary of Rainbow Coral Corp.
(OTCBB:RBCC). The Company continually seeks out new partnerships with
biotechnology developers to deliver profitable new medical technologies and
innovations. For more information on our growth-oriented business initiatives,
please visitwww.RainbowBioSciences.com. For investment information and
performance data on the Company, please
visitwww.RainbowBioSciences.com/investors.html.

Notice Regarding Forward-Looking Statements

Safe Harbor Statement under the Private Securities Litigation Reform Act of
1995: This news release contains forward-looking information within the
meaning of Section 27A of the Securities Act of 1933, as amended, and Section
21E of the Securities Exchange Act of 1934, as amended, including statements
that include the words "believes," "expects," "anticipate" or similar
expressions. Such forward-looking statements involve known and unknown risks,
uncertainties and other factors that may cause the actual results, performance
or achievements of the Company to differ materially from those expressed or
implied by such forward-looking statements. In addition, description of
anyone's past success, either financial or strategic, is no guarantee of
future success. This news release speaks as of the date first set forth above
and the Company assumes no responsibility to update the information included
herein for events occurring after the date hereof.

Contact:

Rainbow Coral Corp.
Patrick Brown, 850-269-7230
President and CEO
info@rainbowcoral.com
 
Press spacebar to pause and continue. Press esc to stop.